» Articles » PMID: 36558965

Vulvodynia: Pain Management Strategies

Overview
Publisher MDPI
Specialty Chemistry
Date 2022 Dec 23
PMID 36558965
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vulvodynia is defined in this international consensus as persistent vulvar pain that occurs for >3 months without an identifiable cause and with several potential associated factors. At present there is no univocal consensus in the therapeutic treatment of vulvodynia. The methods of intervention are based on various aspects including, above all, the management of painful symptoms. Methods: a research on scientific database such as “Pubmed”, “Medline Plus”, “Medscape” was conducted, using the words “women’s genital pain” and “vulvodynia” for the review of the scientific evidence on the assessment and treatment of women’s genital pain. Results: Among the drugs with pain-relieving action, the most effective in the treatment of vulvodynia would seem to be those with antidepressant and anticonvulsant action, even if their mechanisms of action are not known and there are still insufficient studies able to demonstrate their real validity. Among the least effective are non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. However, the ideal would seem to use a combined treatment with multiple types of drugs. Conclusions: Future studies are needed to draw up a unique therapeutic action plan that considers the stratification of patients with vulvodynia and the variability of the symptom.

Citing Articles

Vulvodynia - A contemporary understanding and practical approach in primary care settings.

Amirthalingam S, Nalliah S Malays Fam Physician. 2025; 19():72.

PMID: 39780915 PMC: 11708824. DOI: 10.51866/rv.620.


Chronic Primary Pelvic Pain Syndromes in Women: A Comprehensive Review.

Pinto L, Soutinho M, Coutinho Fernandes M, Taboas M, Leal J, Tome S Cureus. 2025; 16(12):e74918.

PMID: 39742169 PMC: 11688162. DOI: 10.7759/cureus.74918.


Immune mechanisms in vulvodynia: key roles for mast cells and fibroblasts.

Tonc E, Omwanda G, Tovar K, Golden X, Chatterjea D Front Cell Infect Microbiol. 2023; 13:1215380.

PMID: 37360527 PMC: 10285386. DOI: 10.3389/fcimb.2023.1215380.

References
1.
Burrows L, Goldstein A . The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med. 2014; 1(1):30-3. PMC: 4184715. DOI: 10.1002/sm2.4. View

2.
Arnold L, Bachmann G, Rosen R, Kelly S, Rhoads G . Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol. 2006; 107(3):617-24. PMC: 1431685. DOI: 10.1097/01.AOG.0000199951.26822.27. View

3.
Brotto L, Yong P, Smith K, Sadownik L . Impact of a multidisciplinary vulvodynia program on sexual functioning and dyspareunia. J Sex Med. 2014; 12(1):238-47. DOI: 10.1111/jsm.12718. View

4.
Backman H, Widenbrant M, Bohm-Starke N, Dahlof L . Combined physical and psychosexual therapy for provoked vestibulodynia-an evaluation of a multidisciplinary treatment model. J Sex Res. 2008; 45(4):378-85. DOI: 10.1080/00224490802398365. View

5.
Farmer M, Maykut C, Huberman J, Huang L, Khalife S, Binik Y . Psychophysical properties of female genital sensation. Pain. 2013; 154(11):2277-2286. DOI: 10.1016/j.pain.2013.05.028. View